A detailed history of Rhumbline Advisers transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 318,665 shares of BCRX stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
318,665
Previous 299,749 6.31%
Holding current value
$2.69 Million
Previous $1.52 Million 29.37%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$4.13 - $6.79 $78,123 - $128,439
18,916 Added 6.31%
318,665 $1.97 Million
Q1 2024

May 09, 2024

BUY
$4.89 - $7.65 $24,929 - $38,999
5,098 Added 1.73%
299,749 $1.52 Million
Q4 2023

Feb 08, 2024

SELL
$4.98 - $6.77 $3,406 - $4,630
-684 Reduced 0.23%
294,651 $1.76 Million
Q3 2023

Nov 09, 2023

SELL
$6.71 - $7.92 $124,530 - $146,987
-18,559 Reduced 5.91%
295,335 $2.09 Million
Q2 2023

Aug 08, 2023

BUY
$6.96 - $8.81 $19,662 - $24,888
2,825 Added 0.91%
313,894 $2.21 Million
Q1 2023

May 11, 2023

BUY
$7.94 - $11.84 $20,151 - $30,049
2,538 Added 0.82%
311,069 $2.59 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $99,550 - $134,630
9,481 Added 3.17%
308,531 $3.54 Million
Q3 2022

Nov 10, 2022

BUY
$10.79 - $14.81 $214,181 - $293,978
19,850 Added 7.11%
299,050 $3.77 Million
Q2 2022

Aug 11, 2022

SELL
$7.89 - $17.88 $90,103 - $204,189
-11,420 Reduced 3.93%
279,200 $2.95 Million
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $261,810 - $447,524
-22,648 Reduced 7.23%
290,620 $4.73 Million
Q4 2021

Feb 10, 2022

BUY
$11.18 - $15.46 $28,050 - $38,789
2,509 Added 0.81%
313,268 $4.34 Million
Q3 2021

Nov 12, 2021

BUY
$14.21 - $17.65 $105,850 - $131,474
7,449 Added 2.46%
310,759 $4.47 Million
Q2 2021

Aug 05, 2021

BUY
$9.5 - $17.24 $350,008 - $635,173
36,843 Added 13.83%
303,310 $4.8 Million
Q1 2021

May 06, 2021

SELL
$7.37 - $13.61 $235,987 - $435,792
-32,020 Reduced 10.73%
266,467 $2.71 Million
Q4 2020

Feb 10, 2021

BUY
$3.37 - $8.61 $111,183 - $284,061
32,992 Added 12.43%
298,487 $2.22 Million
Q3 2020

Nov 12, 2020

SELL
$3.43 - $5.53 $36,886 - $59,469
-10,754 Reduced 3.89%
265,495 $912,000
Q2 2020

Aug 13, 2020

BUY
$1.9 - $5.61 $166,327 - $491,105
87,541 Added 46.39%
276,249 $1.32 Million
Q1 2020

May 06, 2020

BUY
$1.6 - $4.11 $7,262 - $18,655
4,539 Added 2.46%
188,708 $377,000
Q4 2019

Feb 05, 2020

BUY
$1.59 - $3.45 $14,480 - $31,419
9,107 Added 5.2%
184,169 $635,000
Q3 2019

Oct 23, 2019

BUY
$2.5 - $3.73 $34,077 - $50,843
13,631 Added 8.44%
175,062 $502,000
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $34,617 - $108,848
11,896 Added 7.96%
161,431 $612,000
Q1 2019

May 01, 2019

SELL
$7.38 - $9.72 $2,501 - $3,295
-339 Reduced 0.23%
149,535 $1.22 Million
Q4 2018

Jan 31, 2019

BUY
$6.51 - $9.6 $363,186 - $535,574
55,789 Added 59.3%
149,874 $1.21 Million
Q3 2018

Nov 07, 2018

SELL
$5.52 - $7.99 $4,940 - $7,151
-895 Reduced 0.94%
94,085 $718,000
Q2 2018

Aug 06, 2018

BUY
$4.6 - $6.52 $14,880 - $21,092
3,235 Added 3.53%
94,980 $544,000
Q1 2018

May 02, 2018

BUY
$4.35 - $5.82 $43,282 - $57,909
9,950 Added 12.16%
91,745 $438,000
Q4 2017

Feb 09, 2018

SELL
$4.16 - $5.33 $56,838 - $72,823
-13,663 Reduced 14.31%
81,795 $402,000
Q3 2017

Nov 06, 2017

BUY
$4.1 - $5.97 $391,377 - $569,884
95,458
95,458 $500,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.57B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.